Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRoss SalvarisCKColm KeaneJTJudith Trotman

Discussion

Loading...

Member takes

Overview

Phase Ib/II trial explores BTK inhibitors and mutation testing for improving progression free survival in CNS lymphoma patients, suggesting new strategies may emerge.

Key Points

  • Progression free survival may improve in patients receiving BTK inhibitors alongside immune therapy.
  • Primary CNS lymphoma patients experienced novel treatment strategies with potential effectiveness.
  • Open label multicentre phase Ib/II trial currently recruiting patients across three Australian sites.
  • Combination therapy may highlight the need for further investigation into effective lymphoma treatment options.

Cite This Study

Salvaris et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d57dhttps://doi.org/10.1182/blood-2025-1926
View Full Paper
Ask AI
Bookmark
Share